{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:14:22Z","timestamp":1793884462489,"version":"4.7.0"},"reference-count":149,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T00:00:00Z","timestamp":1553817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T00:00:00Z","timestamp":1553817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s40620-019-00602-5","type":"journal-article","created":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T07:03:02Z","timestamp":1553842982000},"page":"851-870","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["Prevention of complications from use of conventional immunosuppressants: a critical review"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6060-965X","authenticated-orcid":false,"given":"Claudio","family":"Ponticelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Glassock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,3,29]]},"reference":[{"key":"602_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-2895-8_1","volume":"872","author":"DK Granner","year":"2015","unstructured":"Granner DK, Wang JC, Yamamoto KR (2015) Regulatory actions of\u00a0glucocorticoid\u00a0hormones: from organisms to mechanisms. Adv Exp Med Biol 872:3\u201331","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"602_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.tips.2018.11.002","volume":"40","author":"RA Panettieri","year":"2019","unstructured":"Panettieri RA, Schaafsma D, Amrani Y, Koziol-White C, Ostrom R, Tliba O (2019) Non-genomic effects of glucocorticoids: an updated view. Trends Pharmacol Sci 40(1):38\u201349","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"602_CR3","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/j.1552-4604.1997.tb04307.x","volume":"37","author":"KM Tornatore","year":"1997","unstructured":"Tornatore KM, Logue G, Venuto RC, Davis PJ (1997) Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. J Clin Pharmacol 37(4):304\u2013311","journal-title":"J Clin Pharmacol"},{"issue":"16","key":"602_CR4","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMoa1214969","volume":"368","author":"E Boonen","year":"2013","unstructured":"Boonen E, Vervenne H, Meersseman P, Andrew R, Mortier L, Declercq PE, Vanwijngaerden YM, Spriet I, Wouters PJ, Vander Perre S, Langouche L, Vanhorebeek I, Walker BR, Van den Berghe G (2013) Reduced cortisol metabolism during critical illness. N Engl J Med 368(16):1477\u20131488","journal-title":"N Engl J Med"},{"issue":"7","key":"602_CR5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.autrev.2014.02.007","volume":"13","author":"G Moroni","year":"2014","unstructured":"Moroni G, Ponticelli C (2014) Rapidly progressive crescentic glomerulonephritis: early treatment is a must. Autoimmun Rev 13(7):723\u2013729","journal-title":"Autoimmun Rev"},{"key":"602_CR6","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1210\/jc.2008-2380","volume":"94","author":"M Debono","year":"2009","unstructured":"Debono M, Ghobadi C, Rostami-Hodjegan A, Huatan H, Campbell MJ, Newell-Price J, Darzy K, Merke DP, Arlt W, Ross RJ (2009) Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab 94:1548\u20131554","journal-title":"J Clin Endocrinol Metab"},{"key":"602_CR7","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.metabol.2011.06.012","volume":"60","author":"AJ Peckett","year":"2011","unstructured":"Peckett AJ, Wright DC, Riddell MC (2011) The effects of\u00a0glucocorticoids\u00a0on adipose tissue lipid metabolism. Metabolism 60:1500\u20131510","journal-title":"Metabolism"},{"issue":"10","key":"602_CR8","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.molmet.2017.06.013","volume":"6","author":"Y Shen","year":"2017","unstructured":"Shen Y, Roh HC, Kumari M, Rosen ED (2017) Adipocyte glucocorticoid receptor is important in lipolysis and insulin resistance due to exogenous steroids, but not insulin resistance caused by high fat feeding. Mol Metab 6(10):1150\u20131160","journal-title":"Mol Metab"},{"key":"602_CR9","doi-asserted-by":"publisher","first-page":"28648","DOI":"10.1038\/srep28648","volume":"6","author":"HJ Kim","year":"2016","unstructured":"Kim HJ, Cha JY, Seok JW, Choi Y, Yoon BK, Choi H, Yu JH, Song SJ, Kim A, Lee H, Kim D, Han JY, Kim JW (2016) Dexras1 links glucocorticoids to insulin-like growth factor-1 signaling in adipogenesis. Sci Rep 6:28648","journal-title":"Sci Rep"},{"key":"602_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.nutres.2013.12.006","volume":"34","author":"BS Berthon","year":"2014","unstructured":"Berthon BS, MacDonald-Wicks LK, Wood LG (2014) A systematic review of the effect of oral glucocorticoids on energy intake, appetite, and body weight in humans. Nutr Res 34:179\u2013190","journal-title":"Nutr Res"},{"issue":"4","key":"602_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1098-3597(09)80005-7","volume":"9","author":"CP Cannon","year":"2009","unstructured":"Cannon CP, Kumar A (2009) Treatment of overweight and obesity: lifestyle, pharmacologic, and surgical options. Clin Cornerstone 9(4):55\u201368","journal-title":"Clin Cornerstone"},{"issue":"4","key":"602_CR12","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1159\/000365892","volume":"65","author":"XX Liu","year":"2014","unstructured":"Liu XX, Zhu XM, Miao Q, Ye HY, Zhang ZY, Li YM (2014) Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis. Ann Nutr Metab 65(4):324\u2013332","journal-title":"Ann Nutr Metab"},{"issue":"6","key":"602_CR13","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/rheumatology\/kes003","volume":"51","author":"MG Burt","year":"2012","unstructured":"Burt MG, Willenberg VM, Petersons CJ, Smith MD, Ahern MJ, Stranks SN (2012) Screening for diabetes in patients with inflammatory rheumatological disease administered long-term prednisolone: a cross-sectional study. Rheumatology (Oxford) 51(6):1112\u20131119","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"602_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/2040622318779760","volume":"9","author":"KE Trinkley","year":"2018","unstructured":"Trinkley KE, Anderson HD, Nair KV, Malone DC, Saseen JJ (2018) Assessing the incidence of acidosis in patients receiving metformin with and without risk factors for lactic acidosis. Ther Adv Chronic Dis 9(9):179\u2013190","journal-title":"Ther Adv Chronic Dis"},{"issue":"846","key":"602_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejphar.2019.01.002","volume":"5","author":"K Donnan","year":"2019","unstructured":"Donnan K, Segar L (2019) SGLT2 inhibitors and metformin: dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. Eur J Pharmacol 5(846):23\u201329","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"602_CR16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s13104-018-3404-8","volume":"11","author":"K Gunaratne","year":"2018","unstructured":"Gunaratne K, Austin E, Wu PE (2018) Unintentional sulfonylurea toxicity due to a drug\u2013drug interaction: a case report. BMC Res Notes 11(1):331","journal-title":"BMC Res Notes"},{"key":"602_CR17","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1097\/01.tp.0000181165.19788.95","volume":"80","author":"G Villanueva","year":"2005","unstructured":"Villanueva G, Baldwin D (2005) Rosiglitazone therapy of posttransplant diabetes mellitus. Transplantation 80:1402\u20131405","journal-title":"Transplantation"},{"issue":"4","key":"602_CR18","first-page":"505","volume":"16","author":"DE Shorter","year":"2000","unstructured":"Shorter DE, Armstrong PW (2000) Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 16(4):505\u2013511","journal-title":"Can J Cardiol"},{"key":"602_CR19","doi-asserted-by":"publisher","first-page":"3149426","DOI":"10.1155\/2017\/3149426","volume":"2017","author":"X Meng","year":"2017","unstructured":"Meng X, Chen X, Wu L, Zheng S (2017) The hyperlipidemia caused by overuse of glucocorticoid after liver transplantation and the immune adjustment strategy. J Immunol Res 2017:3149426","journal-title":"J Immunol Res"},{"key":"602_CR20","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/art.21329","volume":"53","author":"HK Choi","year":"2005","unstructured":"Choi HK, Seeger JD (2005) Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 53:528\u2013535","journal-title":"Arthritis Rheum"},{"issue":"1","key":"602_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1710-1492-9-30","volume":"9","author":"D Liu","year":"2013","unstructured":"Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, Brown JP, Cohen A, Kim H (2013) A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 9(1):30","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"1","key":"602_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM, REDUCE-it investigators (2019) Cardiovascular risk reduction with Icosapent Ethyl Hypertriglyceridemia. N Engl J Med 380(1):11\u201322","journal-title":"N Engl J Med"},{"key":"602_CR23","doi-asserted-by":"publisher","first-page":"M11","DOI":"10.1530\/EJE-15-0198","volume":"173","author":"MC Coelho","year":"2014","unstructured":"Coelho MC, Dos Santos CV, Vieira Neto L, Gadelha MR (2014) Adverse effects of glucocorticoids: coagulopathy. Eur J Endocrinol 173:M11\u2013M21","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"602_CR24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/0960-0760(92)90077-V","volume":"43","author":"F Mantero","year":"1992","unstructured":"Mantero F, Boscaro M (1992) Glucocorticoid-dependent hypertension. J Steroid Biochem Mol Biol 43(5):409\u2013413","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"8","key":"602_CR25","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/0895-7061(95)00149-J","volume":"8","author":"A Sato","year":"1995","unstructured":"Sato A, Funder JW, Okubo M, Kubota E, Saruta T (1995) Glucocorticoid-induced hypertension in the elderly. Relation to serum calcium and family history of essential hypertension. Am J Hypertens 8(8):823\u2013828","journal-title":"Am J Hypertens"},{"issue":"1","key":"602_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1570161043476483","volume":"2","author":"S Yang","year":"2004","unstructured":"Yang S, Zhang L (2004) Glucocorticoids and vascular reactivity. Curr Vasc Pharmacol 2(1):1\u201312","journal-title":"Curr Vasc Pharmacol"},{"issue":"5","key":"602_CR27","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/00001573-200209000-00014","volume":"17","author":"M Slama","year":"2002","unstructured":"Slama M, Susic D, Frohlich ED (2002) Prevention of hypertension. Curr Opin Cardiol 17(5):531\u2013536","journal-title":"Curr Opin Cardiol"},{"issue":"5","key":"602_CR28","first-page":"703","volume":"102","author":"P Anagnostis","year":"2009","unstructured":"Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP (2009) Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Meatab 102(5):703\u2013708","journal-title":"J Clin Endocrinol Meatab"},{"key":"602_CR29","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1530\/EJE-07-0455","volume":"157","author":"BR Walker","year":"2007","unstructured":"Walker BR (2007) Glucocorticoids and cardiovascular disease. Eur J Endocrinol 157:545\u2013559","journal-title":"Eur J Endocrinol"},{"key":"602_CR30","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1161\/ATVBAHA.114.304454","volume":"35","author":"O Borst","year":"2015","unstructured":"Borst O, Schaub M, Walker B, Schmid E, M\u00fcnzer P, Voelkl J, Alesutan I, Rodr\u00edguez JM, Vogel S, Schoenberger T, Metzger K, Rath D, Umbach A, Kuhl D, M\u00fcller II, Seizer P, Geisler T, Gawaz M, Lang F (2015) Pivotal role of serum- and glucocorticoid-inducible kinase 1 in vascular inflammation and atherogenesis. Arterioscler Thromb Vasc Biol 35:547\u2013557","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"602_CR31","doi-asserted-by":"publisher","first-page":"764","DOI":"10.7326\/0003-4819-141-10-200411160-00007","volume":"141","author":"L Wei","year":"2004","unstructured":"Wei L, MacDonald TM, Walker BR (2004) Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 141:764\u2013770","journal-title":"Ann Intern Med"},{"key":"602_CR32","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1001\/archinternmed.2009.297","volume":"169","author":"CF Christiansen","year":"2009","unstructured":"Christiansen CF, Christensen S, Mehnert F, Cummings SR, Chapurlat RD, S\u00f8rensen HT (2009) Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case\u2013control study. Arch Intern Med 169:1677\u20131683","journal-title":"Arch Intern Med"},{"issue":"1","key":"602_CR33","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1046\/j.1468-1331.2000.00026.x","volume":"7","author":"R Moretti","year":"2000","unstructured":"Moretti R, Torre P, Antonello RM, Zorzon M, Cazzato G (2000) Recurrent atrial fibrillation associated with pulse administration of high doses of methylprednysolone: a possible prophylactic treatment. Eur J Neurol 7(1):130","journal-title":"Eur J Neurol"},{"issue":"6","key":"602_CR34","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1093\/clinids\/11.6.954","volume":"11","author":"AE Stuck","year":"1989","unstructured":"Stuck AE, Minder CE, Frei FJ (1989) Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 11(6):954\u2013963","journal-title":"Rev Infect Dis"},{"issue":"2","key":"602_CR35","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/art.21568","volume":"54","author":"F Wolfe","year":"2006","unstructured":"Wolfe F, Caplan L, Michaud K (2006) Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 54(2):628\u2013634","journal-title":"Arthritis Rheum"},{"issue":"2","key":"602_CR36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jaad.2016.02.1240","volume":"76","author":"A Caplan","year":"2017","unstructured":"Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG (2017) Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Infectious complications and vaccination recommendations. J Am Acad Dermatol 76(2):191\u2013198","journal-title":"J Am Acad Dermatol"},{"key":"602_CR37","doi-asserted-by":"publisher","unstructured":"Herrou J, De Lastours V (2018) Predictive factors of pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214718. (Epub ahead of print)","DOI":"10.1136\/annrheumdis-2018-214718"},{"key":"602_CR38","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1365-2796.1994.tb00855.x","volume":"236","author":"HO Conn","year":"1994","unstructured":"Conn HO, Poynard T (1994) Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 236:619\u2013632","journal-title":"J Intern Med"},{"key":"602_CR39","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1210\/jc.2015-1218","volume":"100","author":"LH Broersen","year":"2015","unstructured":"Broersen LH, Pereira AM, J\u00f8rgensen JO, Dekkers OM (2015) Adrenal insufficiency\u00a0in corticosteroids use: systematic review and meta-analysis. J Clin Endocrinol Metab 100:2171\u20132180","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"602_CR40","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/MOT.0000000000000065","volume":"19","author":"S West","year":"2014","unstructured":"West S, Kenedi C (2014) Strategies to prevent the neuropsychiatric side-effects of corticosteroids: a case report and review of the literature. Curr Opin Organ Transpl 19(2):201\u2013208","journal-title":"Curr Opin Organ Transpl"},{"key":"602_CR41","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/978-1-4939-2895-8_8","volume":"872","author":"B Frenkel","year":"2015","unstructured":"Frenkel B, White W, Tuckermann J (2015) Glucocorticoid-induced osteoporosis. Adv Exp Med Biol 872:179\u2013215","journal-title":"Adv Exp Med Biol"},{"issue":"26","key":"602_CR42","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1056\/NEJMcp1800214","volume":"379","author":"L Buckley","year":"2018","unstructured":"Buckley L, Humphrey MB (2018) Glucocorticoid-induced osteoporosis. N Engl J Med 379(26):2547\u20132556","journal-title":"N Engl J Med"},{"key":"602_CR43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbrc.2015.02.161","volume":"460","author":"H Ding","year":"2015","unstructured":"Ding H, Wang T, Xu D, Cha B, Liu J, Li Y (2015) Dexamethasone-induced apoptosis of osteocytic and osteoblastic cells is mediated by TAK1 activation. Biochem Biophys Res Commun 460:157\u2013163","journal-title":"Biochem Biophys Res Commun"},{"key":"602_CR44","doi-asserted-by":"crossref","unstructured":"Allen CS, Yeung JH, Vandermeer B, Homik J (2016) Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev 10:Cd001347","DOI":"10.1002\/14651858.CD001347.pub2"},{"key":"602_CR45","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1365-2265.1983.tb03198.x","volume":"18","author":"AA Khaleeli","year":"1983","unstructured":"Khaleeli AA, Edwards RH, Gohil K, McPhail G, Rennie MJ, Round J, Ross EJ (1983) Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol (Oxf) 18:155\u2013166","journal-title":"Clin Endocrinol (Oxf)"},{"key":"602_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jbspin.2010.02.025","volume":"78","author":"RM Pereira","year":"2011","unstructured":"Pereira RM, Freire de Carvalho J (2011) Glucocorticoid-induced\u00a0myopathy. Joint Bone Spine 78:41\u201344","journal-title":"Joint Bone Spine"},{"issue":"7","key":"602_CR47","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s10067-013-2214-6","volume":"32","author":"L Carli","year":"2013","unstructured":"Carli L, Tani C, Querci F, Della Rossa A, Vagnani S, Baldini C, Talarico R, d\u2019Ascanio A, Neri R, Tavoni AG, Bombardieri S, Mosca M (2013) Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists\u2019 practice for the monitoring of glucocorticoid eye toxicity. Clin Rheumatol 32(7):1071\u20131073","journal-title":"Clin Rheumatol"},{"issue":"6","key":"602_CR48","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.beem.2016.11.005","volume":"30","author":"E Richmond","year":"2016","unstructured":"Richmond E, Rogol AD (2016) Treatment of growth hormone deficiency in children, adolescents and at the transitional age. Best Pract Res Clin Endocrinol Metab 30(6):749\u2013755","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"602_CR49","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/EJE-16-0905","volume":"177","author":"X Luo","year":"2017","unstructured":"Luo X, Hou L, Liang L, Dong G, Shen S, Zhao Z, Gong CX, Li Y, Du ML, Su Z, Du H, Yan C (2017) Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies. Eur J Endocrinol 177(2):195\u2013205","journal-title":"Eur J Endocrinol"},{"issue":"1\u20132","key":"602_CR50","first-page":"203","volume":"62","author":"JL Zhai","year":"2016","unstructured":"Zhai JL, Ge N, Zhen Y, Zhao Q, Liu C (2016) Corticosteroids significantly increase serum cystatin c concentration without affecting renal function in symptomatic heart failure. Clin Lab 62(1\u20132):203\u2013207","journal-title":"Clin Lab"},{"issue":"1","key":"602_CR51","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/ndt\/14.1.91","volume":"14","author":"LJ Reichert","year":"1999","unstructured":"Reichert LJ, Koene RA, Wetzels JF (1999) Acute haemodynamic and proteinuric effects of prednisolone in patients with a nephrotic syndrome. Nephrol Dial Transpl 14(1):91","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"602_CR52","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S2213-8587(17)30398-4","volume":"6","author":"Andrea M Isidori","year":"2018","unstructured":"Isidori AM, Venneri MA, Graziadio C, Simeoli C, Fiore D, Hasenmajer V, Sbardella E, Gianfrilli D, Pozza C, Pasqualetti P, Morrone S, Santoni A, Naro F, Colao A, Pivonello R, Lenzi A (2018) Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diab Endocrinol 6(3):173\u2013185","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"5","key":"602_CR53","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2215\/CJN.12991117","volume":"13","author":"C Ponticelli","year":"2018","unstructured":"Ponticelli C, Locatelli F (2018) Glucocorticoids in the treatment of glomerular diseases: pitfalls and pearls. Clin J Am Soc Nephrol 13(5):815\u2013822","journal-title":"Clin J Am Soc Nephrol"},{"key":"602_CR54","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.lfs.2018.12.058","volume":"218","author":"J Liu","year":"2019","unstructured":"Liu J, Li X, Fan L, Yang J, Wang J, Sun J, Wang Z (2019) Proton pump inhibitors therapy and risk of bone diseases: an update meta-analysis. Life Sci 218:213\u2013223","journal-title":"Life Sci"},{"issue":"6","key":"602_CR55","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/j.1365-2125.2010.03789.x","volume":"70","author":"Nuala A. Helsby","year":"2010","unstructured":"Helsby NA, Hui CY, Goldthorpe MA, Coller JK, Soh MC, Gow PJ, De Zoysa JZ, Tingle MD (2010) The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation. Br J Clin Pharmacol 70(6):844\u2013853","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"10","key":"602_CR56","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.autrev.2018.04.007","volume":"17","author":"C Ponticelli","year":"2018","unstructured":"Ponticelli C, Escoli R, Moroni G (2018) Does cyclophosphamide still play a role in glomerular diseases? Autoimmun Rev 17(10):1022\u20131027","journal-title":"Autoimmun Rev"},{"issue":"3","key":"602_CR57","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1177\/096120339700600307","volume":"6","author":"F Martin","year":"1997","unstructured":"Martin F, Lauwerys B, Lef\u00e8bvre C, Devogelaer JP, Houssiau FA (1997) Side-effects of intravenous cyclophosphamide pulse therapy. Lupus 6(3):254\u2013257","journal-title":"Lupus"},{"issue":"3","key":"602_CR58","doi-asserted-by":"publisher","first-page":"479","DOI":"10.17219\/acem\/28736","volume":"25","author":"PJ Woytala","year":"2016","unstructured":"Woytala PJ, Morgiel E, \u0141uczak A, Czesak-Woytala K, Wiland P (2016) The safety of intravenous cyclophosphamide in the treatment of rheumatic diseases. Adv Clin Exp Med 25(3):479\u2013484","journal-title":"Adv Clin Exp Med"},{"issue":"1","key":"602_CR59","doi-asserted-by":"publisher","first-page":"c8","DOI":"10.1159\/000319641","volume":"117","author":"LA Herbert","year":"2010","unstructured":"Herbert LA, Rovin BH (2010) Oral cyclophosphamide is on the verge of extinction as therapy for severe autoimmune diseases (especially lupus): should nephrologists care? Nephron Clin Pract 117(1):c8\u2013c14","journal-title":"Nephron Clin Pract"},{"issue":"5","key":"602_CR60","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1681\/ASN.2008101028","volume":"20","author":"Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, S\u00e1nchez-Guerrero J, Solomons N, Wofsy D; Aspreva Lupus Management Study Group","year":"2009","unstructured":"Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, S\u00e1nchez-Guerrero J, Solomons N, Wofsy D; Aspreva Lupus Management Study Group (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20(5):1103\u20131112","journal-title":"J Am Soc Nephrol"},{"key":"602_CR61","first-page":"100","volume":"35","author":"M Faurschou","year":"2008","unstructured":"Faurschou M, Sorensen IJ, Mellemkjaer L, Loft AG, Thomsen BS, Tvede N, Baslund B (2008) Malignancies in Wegener\u2019s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35:100\u2013105","journal-title":"J Rheumatol"},{"key":"602_CR62","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.3899\/jrheum.150065","volume":"42","author":"N Yilmaz","year":"2015","unstructured":"Yilmaz N, Emmungil H, Gucenmez S, Ozen G, Yildiz F, Balkarli A, Kimyon G, Coskun BN, Dogan I, Pamuk ON, Yasar S, Cetin GY, Yazici A, Ergulu Esmen S, Cagatay Y, Yilmaz S, Cefle A, Sayarlioglu M, Kasifoglu T, Karadag O, Pehlivan Y, Dalkilic E, Kisacik B, Cobankara V, Erken E, Direskeneli H, Aksu K, Yavuz S (2015) Incidence of\u00a0cyclophosphamide-induced urotoxicity and protective effect of\u00a0mesna\u00a0in rheumatic diseases. J Rheumatol 42:1664\u20131666","journal-title":"J Rheumatol"},{"key":"602_CR63","doi-asserted-by":"publisher","first-page":"F474","DOI":"10.1152\/ajprenal.00477.2014","volume":"309","author":"S Kim","year":"2015","unstructured":"Kim S, Choi HJ, Jo CH, Park JS, Kwon TH, Kim GH (2015) Cyclophosphamide-induced vasopressin-independent activation of aquaporin-2 in the rat kidney. Am J Physiol Renal Physiol 309:F474\u2013F483","journal-title":"Am J Physiol Renal Physiol"},{"key":"602_CR64","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5527\/wjn.v6.i4.217","volume":"6","author":"P Esposito","year":"2017","unstructured":"Esposito P, Domenech MV, Serpieri N, Calatroni M, Massa I, Avella A, La Porta E, Estienne L, Caramella E, Rampino T (2017) Severe cyclophosphamide-related hyponatremia in a patient with acute glomerulonephritis. World J Nephrol 6:217\u2013220","journal-title":"World J Nephrol"},{"issue":"Suppl 1","key":"602_CR65","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.amjmed.2006.05.003","volume":"119","author":"RH Sterns","year":"2006","unstructured":"Sterns RH, Silver SM (2006) Brain volume regulation in response to hypo-osmolality and its correction. Am J Med 119(Suppl 1):S12\u2013S16","journal-title":"Am J Med"},{"key":"602_CR66","doi-asserted-by":"crossref","unstructured":"Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G, Fenske W, Hoorn EJ, Ichai C, Joannidis M, Soupart A, Zietse R, Haller M, van der Veer S, Van Biesen W, Nagler E; Hyponatraemia Guideline Development Group (2014) Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol Dial Transpl 29[Suppl 2]: i1\u2013i39","DOI":"10.1093\/ndt\/gfu040"},{"key":"602_CR67","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00296-007-0478-3","volume":"28","author":"S Appenzeller","year":"2008","unstructured":"Appenzeller S, Blatyta PF, Costallat LT (2008) Ovarian failure in SLE patients using pulse cyclophosphamide: comparison of different regimes. Rheumatol Int 28:567\u2013571","journal-title":"Rheumatol Int"},{"key":"602_CR68","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/art.40079","volume":"69","author":"F Tamirou","year":"2017","unstructured":"Tamirou F, Husson SN, Gruson D, Debi\u00e8ve F, Lauwerys BR, Houssiau FA (2017) Brief report: the euro-lupus low-dose intravenous cyclophosphamide regimen does not impact the ovarian reserve, as measured by serum levels of anti-m\u00fcllerian hormone. Arthritis Rheumatol 69:1267\u20131271","journal-title":"Arthritis Rheumatol"},{"key":"602_CR69","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s004670000523","volume":"16","author":"K Latta","year":"2001","unstructured":"Latta K, von Schnakenburg C, Ehrich JH (2001) A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Ped Nephrol 16:271\u2013282","journal-title":"Ped Nephrol"},{"key":"602_CR70","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/pbc.22004","volume":"53","author":"ML Meistrich","year":"2009","unstructured":"Meistrich ML (2009) Male gonadal toxicity. Pediatr Blood Cancer 53:261\u2013266","journal-title":"Pediatr Blood Cancer"},{"key":"602_CR71","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/17425255.2017.1277205","volume":"13","author":"E Ghobadi","year":"2017","unstructured":"Ghobadi E, Moloudizargari M, Asghari MH, Abdollahi M (2017) The mechanisms of cyclophosphamide-induced testicular toxicity and the protective agents. Expert Opin Drug Metab Toxicol 13:525\u2013536","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"602_CR72","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/1097-0142(197704)39:4<1403::AID-CNCR2820390408>3.0.CO;2-8","volume":"39","author":"H Koyama","year":"1977","unstructured":"Koyama H, WadaT Nishikawa Y, Iwanaga T, Aoki Y (1977) Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 39(4):1403\u20131409","journal-title":"Cancer"},{"key":"602_CR73","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/humrep\/dev037","volume":"30","author":"N Hasky","year":"2015","unstructured":"Hasky N, Uri-Belapolsky S, Goldberg K, Miller I, Grossman H, Stemmer SM, Ben-Aharon I, Shalgi R (2015) Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma? Hum Reprod 30:1089\u20131101","journal-title":"Hum Reprod"},{"key":"602_CR74","doi-asserted-by":"publisher","first-page":"e0131394","DOI":"10.1371\/journal.pone.0131394","volume":"10","author":"T Nishikawa","year":"2015","unstructured":"Nishikawa T, Miyahara E, Kurauchi K, Watanabe E, Ikawa K, Asaba K, Tanabe T, Okamoto Y, Kawano Y (2015) Mechanisms of Fatal cardiotoxicity following high-dose\u00a0cyclophosphamide\u00a0therapy and a method for its prevention. PLoS ONE 10:e0131394","journal-title":"PLoS ONE"},{"issue":"2","key":"602_CR75","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000196042","volume":"59","author":"Y Usui","year":"1992","unstructured":"Usui Y, Aida H, Kimula Y, Miura H, Aoyagi Y, Nakayama M, Takayama S (1992) A case of cyclophosphamide-induced interstitial pneumonitis diagnosed by bronchoalveolar lavage. Respiration 59(2):125\u2013128","journal-title":"Respiration"},{"key":"602_CR76","doi-asserted-by":"crossref","unstructured":"Barnes H, Holland AE, Westall GP, Goh NS, Glaspole IN (2018) Cyclophosphamide for connective tissue disease-associated interstitial lung disease. Cochrane Database Syst Rev 1:CD010908","DOI":"10.1002\/14651858.CD010908.pub2"},{"key":"602_CR77","doi-asserted-by":"crossref","unstructured":"Ochoa R,\u00a0Bejarano PA, Gl\u00fcck S, Montero AJ (2012) Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and\u00a0cyclophosphamide\u00a0for stage 3 breast cancer: a case report and literature review. J Med Case Rep 6:413","DOI":"10.1186\/1752-1947-6-413"},{"key":"602_CR78","doi-asserted-by":"publisher","first-page":"e0126016","DOI":"10.1371\/journal.pone.0126016","volume":"10","author":"W Shang","year":"2015","unstructured":"Shang W, Ning Y, Xu X et al (2015) Incidence of\u00a0cancer\u00a0in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One 10:e0126016","journal-title":"PLoS One"},{"key":"602_CR79","doi-asserted-by":"publisher","first-page":"e0158360","DOI":"10.1371\/journal.pone.0158360","volume":"11","author":"K Hemminki","year":"2016","unstructured":"Hemminki K, Liu X, Ji J, F\u00f6rsti A (2016) Origin of B-cell neoplasms in autoimmune disease. PLoS One 11:e0158360","journal-title":"PLoS One"},{"issue":"10","key":"602_CR80","first-page":"1022","volume":"17","author":"C Ponticelli","year":"2018","unstructured":"Ponticelli C, Escoli R, Moroni G (2018) Fetal toxicity of immunosuppressive drugs in pregnancy. J Clin Med 17(10):1022\u20131027","journal-title":"J Clin Med"},{"issue":"1","key":"602_CR81","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/00003088-200746010-00002","volume":"46","author":"CE Staatz","year":"2007","unstructured":"Staatz CE, Tett SE (2007) Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 46(1):13\u201358","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"602_CR82","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s13318-016-0378-6","volume":"42","author":"D Zhang","year":"2017","unstructured":"Zhang D, Chow DS (2017) Clinical Pharmacokinetics of mycophenolic acid in hematopoietic stem cell transplantation recipients. Eur J Drug Metab Pharmacokinet 42(2):183\u2013189","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"2","key":"602_CR83","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/00042737-200402000-00014","volume":"16","author":"DJ de Jong","year":"2004","unstructured":"de Jong DJ, Goullet M, Naber TH (2004) Side effects of azathioprine in patients with Crohn\u2019s disease. Eur J Gastroenterol Hepatol 16(2):207\u2013212","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"25","key":"602_CR84","doi-asserted-by":"publisher","first-page":"7795","DOI":"10.3748\/wjg.v21.i25.7795","volume":"21","author":"Gordon W Moran","year":"2015","unstructured":"Moran GW, Dubeau MF, Kaplan GG, Yang H, Eksteen B, Ghosh S, Panaccione R (2015) Clinical predictors of thiopurine-related adverse events in Crohn\u2019s disease. World J Gastroenterol 21(25):7795\u20137804","journal-title":"World Journal of Gastroenterology"},{"issue":"3","key":"602_CR85","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/00004836-200209000-00008","volume":"35","author":"M Regueiro","year":"2002","unstructured":"Regueiro M, Mardini H (2002) Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn\u2019s disease. J Clin Gastroenterol 35(3):240\u2013244","journal-title":"J Clin Gastroenterol"},{"issue":"8","key":"602_CR86","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1136\/gut.34.8.1081","volume":"34","author":"WR Connell","year":"1993","unstructured":"Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE (1993) Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27\u00a0years of experience. Gut 34(8):1081\u20131085","journal-title":"Gut"},{"issue":"8","key":"602_CR87","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0025-7753(00)71540-5","volume":"115","author":"H Corominas","year":"2000","unstructured":"Corominas H, Dom\u00e8nech M, Gonz\u00e1lez-Juan D, Gonz\u00e1lez-Su\u00e1rez B, D\u00edaz C, Pujol J, V\u00e1zquez G, Baiget M (2000) Aplasia after azathioprine administration: role of the thiopurine methyltransferase genetic polymorphism. Med Clin (Barc) 115(8):299\u2013301","journal-title":"Med Clin (Barc)"},{"issue":"7","key":"602_CR88","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/ndt\/11.7.1371","volume":"11","author":"J. F. M. Pruijt","year":"1996","unstructured":"Pruijt JF, Haanen JB, Hollander AA, den Ottolander GJ (1996) Azathioprine-induced pure red-cell aplasia. Nephrol Dial Transpl 11(7):1371\u20131373","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"602_CR89","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.healun.2009.11.602","volume":"29","author":"EL Ohmann","year":"2010","unstructured":"Ohmann EL, Burckart GJ, Brooks MM, Chen Y, Pravica V, Girnita DM, Zeevi A, Webber SA (2010) Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients. J Heart Lung Transpl 29(5):509\u2013516","journal-title":"J Heart Lung Transpl"},{"issue":"7","key":"602_CR90","doi-asserted-by":"publisher","first-page":"e13033","DOI":"10.1111\/petr.13033","volume":"21","author":"Charles D. Varnell","year":"2017","unstructured":"Varnell CD, Fukuda T, Kirby CL, Martin LJ, Warshaw BL, Patel HP, Chand DH, Barletta GM, Van Why SK, VanDe Voorde RG, Weaver DJ, Wilson A, Verghese PS, Vinks AA, Greenbaum LA, Goebel J, Hooper DK (2010) Mycophenolate mofetil-related leukopenia in children and young adults following kidney transplantation: influence of genes and drugs. Pediatr Transpl 21(7). https:\/\/doi.org\/10.1111\/petr.13033","journal-title":"Pediatric Transplantation"},{"issue":"2","key":"602_CR91","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/ndt\/gfl539","volume":"22","author":"J.-P. Rerolle","year":"2006","unstructured":"Rerolle JP, Szelag JC, Le Meur Y (2007) Unexpected rate of severe leucopenia with the association of mycophenolate mofetil and valganciclovir in kidney transplant recipients. Nephrol Dial Transpl 22(2):671\u2013672","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"10","key":"602_CR92","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1432-2277.2004.tb00394.x","volume":"17","author":"KL Hardinger","year":"2004","unstructured":"Hardinger KL, Brennan DC, Lowell J, Schnitzler MA (2004) Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int 17(10):609\u2013616","journal-title":"Transpl Int"},{"key":"602_CR93","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2147\/CEG.S81922","volume":"8","author":"B Manger","year":"2015","unstructured":"Manger B, Hiepe F, Schneider M, Worm M, Wimmer P, Paulus EM, Schwarting A (2015) Impact of switching from\u00a0mycophenolate\u00a0mofetil to enteric-coated\u00a0mycophenolate\u00a0sodium on gastrointestinal side effects in patients with autoimmune disease: a Phase III, open-label, single-arm, multicenter study. Clin Exp Gastroenterol 8:205\u2013213","journal-title":"Clin Exp Gastroenterol"},{"key":"602_CR94","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1080\/00365521.2017.1311936","volume":"52","author":"S Siramolpiwat","year":"2017","unstructured":"Siramolpiwat S, Sakonlaya D (2017) Clinical and histologic features of Azathioprine-induced hepatotoxicity. Scand J Gastroenterol 52:876\u2013880","journal-title":"Scand J Gastroenterol"},{"issue":"9","key":"602_CR95","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/apt.12490","volume":"38","author":"C. O. Musumba","year":"2013","unstructured":"Musumba CO (2013) Review article: the association between\u00a0nodular\u00a0regenerative\u00a0hyperplasia, inflammatory bowel disease and thiopurine therapy. Aliment Pharmacol Ther 38:1025\u201337","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"602_CR96","first-page":"109","volume":"142","author":"B Hantash","year":"2006","unstructured":"Hantash B, Fiorentino D (2006) Liver enzyme abnormalities in patients with atopic dermatitis treated with mycophenolate mofetil. Arch Dermatol 142:109\u2013110","journal-title":"Arch Dermatol"},{"issue":"4","key":"602_CR97","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/01.tp.0000231873.86048.68","volume":"82","author":"A Loupy","year":"2006","unstructured":"Loupy A, Anglichaeu D, Mamzer-Bruneel MF, Martinez F, Thervet E, Legendre C, Serpaggi J, Pol S (2006) Mycophenolate sodium-induced hepatotoxicity: first report. Transplantation 82(4):581","journal-title":"Transplantation"},{"key":"602_CR98","doi-asserted-by":"publisher","first-page":"681482","DOI":"10.1155\/2009\/681482","volume":"2009","author":"Y Kawasaki","year":"2009","unstructured":"Kawasaki Y (2009) Mizoribine: a new approach in the treatment of renal diseases. Clin Dev Immunol 2009:681482","journal-title":"Clin Dev Immunol"},{"key":"602_CR99","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/j.1572-0241.2003.07459.x","volume":"98","author":"A Floyd","year":"2003","unstructured":"Floyd A, Pedersen L, Nielsen GL, Thorlacius-Ussing O, Sorensen HT (2003) Risk of acute pancreatitis in users of\u00a0azathioprine: a population-based case-control study. Am J Gastroenterol 98:1305\u20131308","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"602_CR100","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/00007890-199808150-00026","volume":"66","author":"A Elli","year":"1998","unstructured":"Elli A, Aroldi A, Montagnino G, Tarantino A, Ponticelli C (1998) Mycophenolate mofetil and cough. Transplantation 66(3):409","journal-title":"Transplantation"},{"key":"602_CR101","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/ndt\/17.5.923","volume":"17","author":"B Maes","year":"2002","unstructured":"Maes B, Oellerich M, Ceuppens JL, Armstrong VW, Evenepoel P, Kuypers D, Messiaen T, Shipkova M, Wieland E, Vanrenterghem Y (2002) A new\u00a0acute\u00a0inflammatory\u00a0syndrome\u00a0related to the introduction of\u00a0mycophenolate\u00a0mofetil in patients with Wegener\u2019s granulomatosis. Nephrol Dial Transpl 17:923\u2013926","journal-title":"Nephrol Dial Transpl"},{"key":"602_CR102","first-page":"198","volume":"12","author":"F Moreso","year":"1998","unstructured":"Moreso F, Seron D, Morales JM, Cruzado JM, Gil-Vernet S, P\u00e9rez JL, Fulladosa X, Andr\u00e9s A, Griny\u00f3 JM (1998) Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses. Clin Transpl 12:198\u2013205","journal-title":"Clin Transpl"},{"issue":"12","key":"602_CR103","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1097\/TP.0b013e3182921995","volume":"95","author":"C Borni-Duval","year":"2013","unstructured":"Borni-Duval C, Caillard S, Olagne J, Perrin P, Braun-Parvez L, Heibel F, Moulin B (2013) Risk factors for BK virus infection in the era of therapeutic drug monitoring. Transplantation 95(12):1498\u20131505","journal-title":"Transplantation"},{"key":"602_CR104","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000454876","volume":"9","author":"M Aleissa","year":"2017","unstructured":"Aleissa M, Nicol P, Godeau M, Tournier E, de Bellissen F, Robic MA, Livideanu CB, Mazereeuw-Hautier J, Paul C (2017) Azathioprine hypersensitivity syndrome: two cases of febrile neutrophilic dermatosis induced by azathioprine. Case Rep Dermatol 9:6\u201311","journal-title":"Case Rep Dermatol"},{"issue":"1","key":"602_CR105","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1006\/gyno.1997.4632","volume":"65","author":"B Volgger","year":"1997","unstructured":"Volgger B, Marth C, Zeimet A, M\u00fcller-Holzner E, Ruth N, Dapunt O (1997) Fulminant course of a microinvasive vulvar carcinoma in an immunosuppressed woman. Gynecol Oncol 65(1):177\u2013179","journal-title":"Gynecol Oncol"},{"key":"602_CR106","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/0192623311427711","volume":"40","author":"JL Weaver","year":"2012","unstructured":"Weaver JL (2012) Establishing the carcinogenic\u00a0risk of\u00a0immunomodulatory drugs. Toxicol Pathol 40:267\u2013271","journal-title":"Toxicol Pathol"},{"issue":"4","key":"602_CR107","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/ijd.13409","volume":"56","author":"HC Perez","year":"2017","unstructured":"Perez HC, Benavides X, Perez JS, Pabon MA, Tschen J, Maradei-Anaya SJ, Lopez L, Lozano E (2017) Basic aspects of the pathogenesis and prevention of non-melanoma skin cancer in solid organ transplant recipients: a review. Int J Dermatol 56(4):370\u2013378","journal-title":"Int J Dermatol"},{"key":"602_CR108","doi-asserted-by":"crossref","unstructured":"Casetta I, Iuliano G, Filippini G (2007) Azathioprine for multiple sclerosis. Cochrane Database Syst Rev 4:CD003982","DOI":"10.1002\/14651858.CD003982.pub2"},{"key":"602_CR109","doi-asserted-by":"publisher","first-page":"e81702","DOI":"10.1371\/journal.pone.0081702","volume":"8","author":"B Dun","year":"2013","unstructured":"Dun B, Sharma A, Teng Y, Liu H, Purohit S, Xu H, Zeng L, She JX (2013) Mycophenolic acid inhibits migration and invasion of gastric cancer cells via multiple molecular pathways. PLoS One 8:e81702","journal-title":"PLoS One"},{"issue":"5","key":"602_CR110","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1586\/1744666X.2015.1033404","volume":"11","author":"C Ponticelli","year":"2015","unstructured":"Ponticelli C, Moroni G (2015) Immunosuppression in pregnant women with systemic lupus erythematosus. Expert Rev Clin Immunol 11(5):549\u2013552","journal-title":"Expert Rev Clin Immunol"},{"key":"602_CR111","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/357692a0","volume":"357","author":"SJ O\u2019Keefe","year":"1992","unstructured":"O\u2019Keefe SJ, Tamura J, Kincaid RL, Tocci MJ, O\u2019Neill EA (1992) FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 357:692\u2013694","journal-title":"Nature"},{"issue":"3","key":"602_CR112","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2165\/11317350-000000000-00000","volume":"49","author":"CE Staatz","year":"2010","unstructured":"Staatz CE, Goodman LK, Tett SE (2010) Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet 49(3):141\u2013175","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"602_CR113","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3109\/03602532.2016.1151037","volume":"48","author":"T Vanhove","year":"2016","unstructured":"Vanhove T, Annaert P, Kuypers DR (2016) Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metab Rev 48(1):88\u2013112","journal-title":"Drug Metab Rev"},{"issue":"2","key":"602_CR114","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.trre.2016.09.001","volume":"31","author":"T Vanhove","year":"2017","unstructured":"Vanhove T, Remijsen Q, Kuypers D, Gillard P (2017) Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus. Transpl Rev (Orlando) 31(2):69\u201377","journal-title":"Transpl Rev (Orlando)"},{"issue":"12","key":"602_CR115","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1038\/sj.ki.5002553","volume":"72","author":"D.C. Cattran","year":"2007","unstructured":"Cattran DC, Alexopoulos E, Heering P, Hoyer PF, Johnston A, Meyrier A, Ponticelli C, Saito T, Choukroun G, Nachman P, Praga M, Yoshikawa N (2007) Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int 72(12):1429\u20131447","journal-title":"Kidney International"},{"issue":"2","key":"602_CR116","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2215\/CJN.04800908","volume":"4","author":"Maarten Naesens","year":"2009","unstructured":"Naesens M, Kuypers DR, Sarwal M (2009) Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4(2):481\u2013508","journal-title":"Clinical Journal of the American Society of Nephrology"},{"key":"602_CR117","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S0270-9295(03)00090-1","volume":"23","author":"EA Burdmann","year":"2003","unstructured":"Burdmann EA, Andoh TF, Yu L, Bennett WM (2003) Cyclosporine nephrotoxicity. Semin Nephrol 23:465\u2013476","journal-title":"Semin Nephrol"},{"issue":"10","key":"602_CR118","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1093\/qjmed\/89.10.751","volume":"89","author":"M.H. Griffiths","year":"1996","unstructured":"Griffiths MH, Crowe AV, Papadaki L, Banner NR, Yacoub MH, Thompson FD, Neild GH (1996) Cyclosporin nephrotoxicity in heart and lung transplant patients. QJM 89(10):751\u2013763","journal-title":"QJM"},{"issue":"4","key":"602_CR119","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/ki.1996.415","volume":"50","author":"WM Bennett","year":"1996","unstructured":"Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM (1996) Chronic cyclosporine nephropathy: the Achilles\u2019 heel of immunosuppressive therapy. Kidney Int 50(4):1089\u20131100","journal-title":"Kidney Int"},{"issue":"6","key":"602_CR120","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1159\/000351648","volume":"37","author":"N Issa","year":"2013","unstructured":"Issa N, Kukla A, Ibrahim HN (2013) Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence. Am J Nephrol 37(6):602\u2013612","journal-title":"Am J Nephrol"},{"issue":"5","key":"602_CR121","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s11906-002-0067-5","volume":"4","author":"JJ Curtis","year":"2002","unstructured":"Curtis JJ (2002) Hypertensinogenic mechanism of the calcineurin inhibitors. Curr Hypertens Rep 4(5):377\u2013380","journal-title":"Curr Hypertens Rep"},{"key":"602_CR122","doi-asserted-by":"publisher","first-page":"F489","DOI":"10.1152\/ajprenal.00575.2016","volume":"312","author":"KI Blankenstein","year":"2017","unstructured":"Blankenstein KI, Borschewski A, Labes R et al (2017) Calcineurin inhibitor cyclosporine A activates renal Na-K-Cl cotransporters via local and systemic mechanisms. Am J Physiol Renal Physiol 312:F489\u2013F501","journal-title":"Am J Physiol Renal Physiol"},{"key":"602_CR123","doi-asserted-by":"crossref","unstructured":"Robert N, Wong GW, Wright JM (2010) Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev 1:CD007893","DOI":"10.1002\/14651858.CD007893.pub2"},{"key":"602_CR124","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.pharep.2015.08.012","volume":"68","author":"E Grze\u015bk","year":"2016","unstructured":"Grze\u015bk E, Malinowski B, Wici\u0144ski M et al (2016) Cyclosporine-A, but not tacrolimus significantly increases reactivity of vascular smooth muscle cells. Pharmacol Rep 68:201\u2013205","journal-title":"Pharmacol Rep"},{"key":"602_CR125","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/00007890-200203150-00012","volume":"73","author":"IH Klein","year":"2002","unstructured":"Klein IH, Abrahams A, van Ede T, Hene RJ, Koomans HA, Ligtenberg G (2002) Different effects of tacrolimus andcyclosporine on renal hemodynamic and blood pressure in healthy subjects. Transplantation 73:732","journal-title":"Transplantation"},{"issue":"2","key":"602_CR126","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s40620-017-0378-x","volume":"30","author":"C Ponticelli","year":"2017","unstructured":"Ponticelli C, Cucchiari D (2017) Renin-angiotensin system inhibitors in kidney transplantation: a benefit-risk assessment. J Nephrol 30(2):155\u2013157","journal-title":"J Nephrol"},{"issue":"8","key":"602_CR127","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1097\/01.TP.0000137793.23371.42","volume":"78","author":"D R. J. Kuypers","year":"2004","unstructured":"Kuypers DR, Neumayer HH, Fritsche L, Budde K, Rodicio JL, Vanrenterghem Y (2004) Lacidipine Study Group. Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study. Transplantation 78(8):1204\u20131211","journal-title":"Transplantation"},{"issue":"1","key":"602_CR128","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1476-5381.2010.01018.x","volume":"162","author":"LA \u00d8zbay","year":"2010","unstructured":"\u00d8zbay LA, Smidt K, Mortensen DM Carstens J, J\u00f8rgensen KA, Rungby J (2011) Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells. Br J Pharmacol 162: 136\u2013146","journal-title":"British Journal of Pharmacology"},{"key":"602_CR129","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/cpt.546","volume":"101","author":"HA Chakkera","year":"2017","unstructured":"Chakkera HA, Kudva Y, Kaplan B (2017) Calcineurin inhibitors: pharmacologic mechanisms impacting both insulin resistance and insulin secretion leading to glucose dysregulation and diabetes mellitus. Clin Pharmacol Ther 101:114\u2013120","journal-title":"Clin Pharmacol Ther"},{"key":"602_CR130","doi-asserted-by":"publisher","first-page":"e0143405","DOI":"10.1371\/journal.pone.0143405","volume":"10","author":"Z Li","year":"2015","unstructured":"Li Z, Sun F, Zhang Y, Chen H, He N, Chen H, Song P, Wang Y, Yan S, Zheng S (2015) Tacrolimus induces insulin resistance and increases the glucose absorption in the jejunum: a potential mechanism of the diabetogenic effects. PLoS One 10:e0143405","journal-title":"PLoS One"},{"issue":"11","key":"602_CR131","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1111\/ajt.14323","volume":"17","author":"J Tri\u00f1anes","year":"2017","unstructured":"Tri\u00f1anes J, Rodriguez-Rodriguez AE, Brito-Casillas Y, Wagner A, De Vries APJ, Cuesto G, Acebes A, Salido E, Torres A, Porrini E (2017) Deciphering tacrolimus-induced toxicity in pancreatic \u03b2 cells. Am J Transpl 17(11):2829\u20132840","journal-title":"Am J Transpl"},{"key":"602_CR132","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s11010-017-2945-9","volume":"429","author":"SR Rao","year":"2017","unstructured":"Rao SR, Sundararajan S, Subbarayan R, Murugan Girija D (2017) Cyclosporine-A induces endoplasmic reticulum stress and influences pro-apoptotic factors in human gingival fibroblasts. Mol Cell Biochem 429:179\u2013185","journal-title":"Mol Cell Biochem"},{"issue":"12","key":"602_CR133","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1097\/00007890-199806270-00012","volume":"65","author":"MM Nash","year":"1998","unstructured":"Nash MM, Zalztman JS (1998) Efficacy of azithromycin in the treatment of cyclosporine-induced gingival hyperplasia in renal transplant recipients. Transplantation 65(12):1611\u20131615","journal-title":"Transplantation"},{"issue":"2","key":"602_CR134","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1600-0765.2011.01418.x","volume":"47","author":"R. Hirsch","year":"2011","unstructured":"Hirsch R, Deng H, Laohachai MN (2012) Azithromycin in periodontal treatment: more than an antibiotic. J Periodontal Res 47(2):137\u2013148","journal-title":"Journal of Periodontal Research"},{"issue":"1","key":"602_CR135","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ccc.2018.08.011","volume":"35","author":"A Sen","year":"2019","unstructured":"Sen A, Callisen H, Libricz S, Patel B (2019) Complications of solid organ transplantation: cardiovascular, neurologic, renal, and gastrointestinal. Crit Care Clin 35(1):169\u2013186","journal-title":"Crit Care Clin"},{"key":"602_CR136","first-page":"521","volume":"18","author":"C Ponticelli","year":"2005","unstructured":"Ponticelli C, Campise R (2005) Neurological complications in kidney transplant recipients. J Nephrol 18:521\u2013528","journal-title":"J Nephrol"},{"key":"602_CR137","doi-asserted-by":"publisher","first-page":"e3173","DOI":"10.1097\/MD.0000000000003173","volume":"95","author":"T Song","year":"2016","unstructured":"Song T, Rao Z, Tan Q, Qiu Y, Liu J, Huang Z, Wang X, Lin T (2016) Calcineurin inhibitors associated posterior reversible encephalopathy syndrome in solid organ transplantation: report of 2 cases and literature review. Medicine (Baltimore) 95:e3173","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"602_CR138","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1161\/ATVBAHA.115.307030","volume":"36","author":"M Kockx","year":"2016","unstructured":"Kockx M, Glaros E, Leung B, Ng TW, Berb\u00e9e JF, Deswaerte V, Nawara D, Quinn C, Rye KA, Jessup W, Rensen PC, Meikle PJ, Kritharides L (2016) Low-density lipoprotein receptor-dependent and low-density lipoprotein receptor-independent mechanisms of cyclosporin a-induced dyslipidemia. Arterioscler Thromb Vasc Biol 36(7):1338\u20131349","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"602_CR139","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1074\/jbc.M112.419150","volume":"288","author":"HY Suk","year":"2013","unstructured":"Suk HY, Zhou C, Yang TT, Zhu H, Yu RY, Olabisi O, Yang X, Brancho D, Kim JY, Scherer PE, Frank PG, Lisanti MP, Calvert JW, Lefer DJ, Molkentin JD, Ghigo A, Hirsch E, Jin J, Chow CW (2013) Ablation of calcineurin A\u03b2 reveals\u00a0hyperlipidemia\u00a0and signaling cross-talks with phosphodiesterases. J Biol Chem 288:3477\u20133488","journal-title":"J Biol Chem"},{"key":"602_CR140","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.bcp.2014.01.020","volume":"88","author":"A Fuhrmann","year":"2014","unstructured":"Fuhrmann A, Lopes P, Sereno J, Pedro J, Espinoza DO, Pereira MJ, Reis F, Eriksson JW, Carvalho E (2014) Molecular mechanisms underlying the effects of cyclosporin A and sirolimus on glucose and\u00a0lipid\u00a0metabolism in liver, skeletal muscle and adipose tissue in an in vivo rat model. Biochem Pharmacol 88:216\u2013228","journal-title":"Biochem Pharmacol"},{"key":"602_CR141","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1139\/cjpp-2013-0250","volume":"92","author":"DR Brocks","year":"2014","unstructured":"Brocks DR, Chaudhary HR, Ben-Eltriki M, Elsherbiny ME, El-Kadi AO (2014) Effects of serum lipoproteins on\u00a0cyclosporine.\u00a0A cellular uptake and renal toxicity in vitro. Can J Physiol Pharmacol 92:140\u2013148","journal-title":"Can J Physiol Pharmacol"},{"issue":"15","key":"602_CR142","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0024-3205(99)00064-8","volume":"64","author":"H Clarke","year":"1999","unstructured":"Clarke H, Ryan MP (1999) Cyclosporine A-induced alterations in magnesium homeostasis in the rat. Life Sci 64(15):1295\u20131306","journal-title":"Life Sci"},{"issue":"3","key":"602_CR143","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/ki.1994.317","volume":"46","author":"Janice P. Lea","year":"1994","unstructured":"Lea JP, Sands JM, McMahon SJ, Tumlin J (1994) Evidence that the inhibition of Na+\/K(+)-ATPase activity by FK506 involves calcineurin. Kidney Int 46:647\u2013652","journal-title":"Kidney International"},{"issue":"8","key":"602_CR144","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1016\/j.transproceed.2010.08.016","volume":"42","author":"J.M. Osorio","year":"2010","unstructured":"Osorio JM, Bravo J, P\u00e9rez A, Ferreyra C, Osuna A (2010) Magnesemia in renal transplant recipients: relation with immunosuppression and posttransplant diabetes. Transpl Proc 42(8):2910\u20132913","journal-title":"Transplantation Proceedings"},{"issue":"18","key":"602_CR145","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.2165\/00003495-200565180-00004","volume":"65","author":"L Stamp","year":"2005","unstructured":"Stamp L, Searle M, O\u2019Donnell J, Chapman P (2005) Gout in solid organ transplantation: a challenging clinical problem. Drugs 65(18):2593\u20132611","journal-title":"Drugs"},{"key":"602_CR146","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1093\/ndt\/gfw232","volume":"31","author":"GB Piccoli","year":"2016","unstructured":"Piccoli GB, Cabiddu G, Attini R, Gerbino M, Todeschini P, Perrino ML, Mone AM, Piredda GB, Gnappi E, Caputo F et al (2016) Pregnancy outcomes after kidney graft in Italy: are the changes over time the result of different therapies or of different policies? A nationwide survey (1978\u20132013). Nephrol Dial Transpl 31:1957\u20131965","journal-title":"Nephrol Dial Transpl"},{"key":"602_CR147","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7182\/pit2013803","volume":"23","author":"KM Thiagarajan","year":"2013","unstructured":"Thiagarajan KM, Arakali SR, Mealey KJ, Cardonick EH, Gaughan WJ, Davison JM, Moritz MJ, Armenti VT (2013) Safety considerations: breastfeeding after transplant. Prog. Transpl 23:137\u2013146","journal-title":"Prog. Transpl"},{"key":"602_CR148","doi-asserted-by":"crossref","unstructured":"Euvrard S,Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, Broeders N, del Marmol V, Chatelet V, Dompmartin A, Kessler M, Serra AL, Hofbauer GF, Pouteil-Noble C, Campistol JM, Kanitakis J, Roux AS, Decullier E, Dantal J; TUMORAPA Study Group (2014). Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 367(4):329\u2013339","DOI":"10.1056\/NEJMoa1204166"},{"key":"602_CR149","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1097\/TP.0b013e3182007be2","volume":"90","author":"A Liacini","year":"2010","unstructured":"Liacini A, Seamone ME, Muruve DA, Tibbles LA (2010) Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection. Transplantation 90:1450\u20131457","journal-title":"Transplantation"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-019-00602-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-019-00602-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-019-00602-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:56:12Z","timestamp":1777564572000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/32\/6\/851\/8328179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,29]]},"references-count":149,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["602"],"URL":"https:\/\/doi.org\/10.1007\/s40620-019-00602-5","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,29]]},"assertion":[{"value":"15 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr Ponticelli has no conflict of interest to disclose. Dr. Glassock is a compensated consultant to Bristol-Myers Squibb, Genentech, Chemocentryx, Mallinckrodt, Apellis, Ionis, Achillion, Omeros. He also receives a stipend from Wolters -Kluwer (UpToDate) and Karger Publications (American Journal of Nephrology and Nephrology Viewpoints) for Editorial Services. He owns stock in REATA, Inc. (Bardoxolone).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}